SAVA
Filana Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Price chart
Jul 15Jul 20Jul 23Jul 28Jul 31Aug 5Aug 10Aug 13
Key dataAug 13, 2026
Open$0.93
From 52W high−71.55%
Volume68429.00
Market cap$63.75M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataAug 13, 2026
Open
$0.93
From 52W high
−71.55%
Volume
68429.00
Market cap
$63.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
+2.33%
YTD Return
−52.68%
SummaryUpdated Dec 1, 2025
Cassava Sciences, Inc. (NASDAQ:SAVA) is a clinical-stage biotechnology company founded in 1998 and originally incorporated as Pain Therapeutics, Inc. before changing its name in March 2019. Based in Austin, Texas, the company has pivoted from pain management to focus exclusively on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company went public in 2000 and has spent over two decades developing its lead drug candidate, simufilam, which is currently in Phase 3 clinical trials for Alzheimer's disease treatment.
Similar companies
Latest newsMore news →
Filana Therapeutics director, president and CEO Richard Barry bought 306,813 shares of the company for $278,132, per a Form 4 filed with the SEC.18d agoThe U.S. Food and Drug Administration lifted the clinical hold on Filana Therapeutics' investigational new drug application for simufilam, enabling a planned Phase 2a study in patients aged 12 to 55 with TSC-related epilepsy.27d ago